NASD · Healthcare · Biotechnology · USA
Viridian Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Viridian Therapeutics is a biopharmaceutical company developing medicines for serious and rare autoimmune diseases. The company is advancing anti-IGF-1R candidates for thyroid eye disease, FcRn inhibitors for autoimmune disorders, and a TSHR inhibitor program. Viridian conducts internal research and in-licensing, with capabilities in protein discovery, biologics manufacturing, and clinical development.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Viridian Therapeutics Inc stock.
Overvalued: intrinsic value $6.31 per share, market price $30.06, margin of safety -376.1% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $6.31; the price of $30.06 is 376% above that value.
17 more funds hold it; the full list is part of the paid plan.
84 more in this industry show a wider margin of safety.
VRDN is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $6.31; the price of $30.06 is 376% above that value.
$6.31 per share (as of the 2026-11-17 close), against a market price of $30.06. That is a margin of safety of -376.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.